Spatiotemporally Controlled Bioorthogonal Prodrug Activation for Precise Chemotherapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Uncontrolled anticancer drug pharmacokinetics lead to off-target accumulation, reducing efficacy and increasing toxicity.
• Developing strategies for precise drug activation at tumor sites is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To develop a spatiotemporally controlled inverse electron demand Diels-Alder reaction (SC-IEDDA) strategy for in situ prodrug activation.
• To enhance chemotherapy precision and safety by targeting tumor tissues.

Main Methods:

• Utilized two nanoplatforms: pH-sensitive ZIF-8 nanoparticles with caged doxorubicin (TCO-DOX) and NIR light-responsive nanomicelles with indocyanine green (ICG) and tetrazine (Tz).
• Leveraged tumor acidity for ZIF-8 degradation and NIR light-induced reactive oxygen species for linker cleavage, releasing TCO-DOX and Tz.
• Triggered bioorthogonal IEDDA reaction between TCO-DOX and Tz specifically within the tumor microenvironment.

Main Results:

• The dual-nanoparticle system prevented premature prodrug release during circulation.
• Tumor-specific conditions (acidity and NIR light) successfully initiated the sequential release of prodrug and activator.
• The bioorthogonal IEDDA reaction efficiently uncaged doxorubicin at the tumor site, demonstrating precise chemotherapy activation.

Conclusions:

• The SC-IEDDA strategy enables precise, localized chemotherapy by controlling prodrug activation within tumor tissues.
• This approach significantly improves the safety profile of anticancer drugs by minimizing exposure to healthy tissues.
• The developed nanoplatform strategy represents a significant advancement for precision oncology and effective cancer therapy.